- Today's Annual General Meeting was the first one following the
change in legal form completed in November
2023
- Shareholders voted in favor of the proposed dividend of
1.19 euros, representing an increase
of around 6 percent compared to the previous year
- New compensation system for Management Board approved
- Ambitious growth targets for 2024 confirmed
BAD HOMBURG, Germany, May 16, 2024
/PRNewswire/ -- Fresenius Medical Care (FME), the global
leader in providing products and services for people with kidney
diseases, is executing its strategic turnaround plan and is well on
track to achieve its goals for 2024.
At today's Annual General Meeting, Michael Sen, Chairman of the Supervisory
Board of Fresenius Medical Care AG, said: "Fresenius Medical Care
has made significant progress in 2023. The consistent
implementation of the transformation program is beginning to pay
off. The deconsolidation and the independence are providing
Fresenius Medical Care with everything it needs to further
strengthen its position in the dialysis market and to realize its
full potential."
Michael Sen added: "On behalf of
the Supervisory Board, I would like to thank the members of the
Management Board under the leadership of CEO Helen Giza for their trusting cooperation and
very good performance in the past financial year. The newly
composed management team has the necessary expertise, energy, and
experience to take the company forward in the interests of
patients, employees, and shareholders."
Helen Giza, CEO of
Fresenius Medical Care AG, said: "For 2023, we delivered top- and
bottom-line growth, and exceeded our operating income outlook that
we raised twice. Our FME25 transformation program is ahead of
schedule and our portfolio optimization program is well underway.
All our achievements mark a highly successful conclusion to an
exceptional year of transformation and turnaround efforts."
"Turning to 2024, this year is being spent in singular focus on
disciplined execution and value creation. While 2023 was a year of
level-setting, 2024 is one of momentum-building," said Giza. The
CEO thanked employees for their dedication and commitment to
ensuring high-quality care for patients worldwide.
A significant majority of 96.97 percent of shareholders approved
the dividend proposal for fiscal year 2023 of 1.19 euros, representing an increase of around 6
percent compared to the previous year (2022: 1.12 euros). The proposal aligns with the
dividend policy of the company to adjust payouts according to Group
net income development (excluding special items).
The shareholders also approved, with a majority of 87.58
percent, the new Management Board's compensation system.
With a majority of 99.49 percent, the shareholders also approved
the update to the Supervisory Board's remuneration.
The Management Board and the Supervisory Board were discharged
for the year 2023 with majorities of 98.71 percent and 98.42
percent, respectively.
At the Annual General Meeting, 88.39 percent of the share
capital was represented.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products
and services for people with kidney diseases, of whom approximately
4.1 million patients worldwide receive regular dialysis treatment.
Through its network of 3,862 dialysis centers, Fresenius Medical
Care provides dialysis treatment for approximately 325,000 patients
worldwide and is the leading provider of dialysis products such as
dialysis machines and dialyzers. Fresenius Medical Care is listed
on the Frankfurt Stock Exchange (FME) and the New York Stock
Exchange (FMS).
For further information, please
visit www.freseniusmedicalcare.com/de.
Legal Disclaimer:
This communication contains forward-looking statements, which are
subject to various risks and uncertainties. Future results may
differ significantly from the currently expected results due to
various factors such as changes in the business, economic, and
competitive situation, changes in laws, regulatory approvals, the
impact of the Covid-19 pandemic, results of clinical studies,
exchange rate fluctuations, uncertainties regarding litigation or
investigative proceedings, and the availability of financial
resources. These and other risks and uncertainties are described in
detail in the reports of Fresenius Medical Care AG filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care AG
assumes no obligation to update the forward-looking statements
contained in this communication.
Media Contact
Christine Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for Analysts and Investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com/de
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-annual-general-meeting-company-makes-significant-progress-in-its-transformation-efforts-and-confirms-its-ambitious-2024-growth-targets-302147875.html
SOURCE Fresenius Medical Care Holdings, Inc.